Jacqueline Norris-Drouin
Senior Scientist
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
DNA-encoded library (DEL) technology has become a powerful tool in modern drug discovery. Fully harnessing its potential requires the use of extensive computational methodologies, which are often available only through proprietary software. This restricts accessibility for small teams lacking robust informatics support, hindering the growth of the technology. Here, we present DELi, an open-source DEL informatics platform designed for library design, NGS decoding and calling, and enrichment analysis. DELi supports a simple and easy to understand configuration setup to present a straightforward user interface. To showcase its capabilities, we used DELi to design an in-house custom, benzimidazole-based DEL (UNC DEL006), and performed proof-of-concept selection experiments against Bromodomain-containing Protein 4 (BRD4). The DELi decoding and analysis modules identified top-performing compounds, leading to the off-DNA synthesis of UNC11951, which was confirmed as a nanomolar BRD4 binder via isothermal titration calorimetry (ITC) and differential scanning fluorimetry (DSF). These results demonstrate DELi as an effective tool for DEL design and analysis. Furthermore, its open-source nature will promote ongoing development and contributions from the DEL community to expand its applications and capabilities, making DEL technology more widely accessible. Abstract Figure
Year:
2025
A promising drug target, SETDB1, is a dual Kme reader and methyltransferase, which has been implicated in cancer and neurodegenerative disease progression. To help understand the role of the triple Tudor domain (3TD) of SETDB1, its Kme reader, we first identified a low micromolar small molecule ligand, UNC6535, which occupies simultaneously both the TD2 and TD3 reader binding sites. Further optimization led to the discovery of UNC10013, the first covalent 3TD ligand targeting Cys385 of SETDB1. UNC10013 is potent with a k inact /K I of 1.0 x 10 6 M -1 s -1 and demonstrated proteome-wide selectivity. In cells, negative allosteric modulation of SETDB1-mediated Akt methylation was observed after treatment with UNC10013. Therefore, UNC10013 is a potent, selective and cell-active covalent ligand for the 3TD of SETDB1, demonstrating negative allosteric modulator properties and making it a promising tool to study the biological role of SETDB1 in disease progression.
Year:
2024
Collaborators (9)
Dalia Barsyte-Lovejoy
University of Toronto
Cheryl H. Arrowsmith
Chief Scientist
University of Toronto
Robert K. McGinty
Associate Professor
University of North Carolina at Chapel Hill
Stephen V. Frye
University of North Carolina at Chapel Hill
Konstantin Popov
Associate Professor
University of North Carolina at Chapel Hill
Pengda Liu
Associate Professor
University of North Carolina at Chapel Hill
Kenneth H. Pearce
Research Professor
University of North Carolina at Chapel Hill
Melanie Uguen
University of North Carolina at Chapel Hill
Levon Halabelian
Assistant Professor
University of Toronto
Make your next move.
Prepare your application
Review drafts before you send them.